TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03334669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents Connect for Healthy Living (PConnect)
Description: Parents Connect for Healthy Living (PConnect) parent curriculum: This 10-week program (20 hours total) engages Head Start parents in a wide range of topics related to health and empowerment and is designed to foster a safe, open forum through which parents can connect with other parents and mobilize resources to support their family's health; NOTE: The PConnect program was not implemented in 2019-2020 due to the coronavirus pandemic. In 2020-2021, PConnect was implemented virtually; these are pilot data and not part of the main trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Nutrition Support
Description: Enhanced Nutrition Support: Existing nutrition resources within Head Start (e.g., Biannual child health letters) are expanded and improved to ensure parents are aware of their child's weight status and are linked with age-appropriate weight management services if their child has overweight or obesity. NOTE: Enhanced nutrition support was not implemented in spring 2020 due to the pandemic. In 2020-2021, it was moved to a virtual format in what will be a pilot virtual trial.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Media Resources
Description: Media Resources: Print and online resources that employ consistent messaging to reach parents and ensure that behavior change messages are accessible to families. NOTE: Due to the pandemic, media resources were not shared in spring 2020. They were implemented in virtual format in 2020-2021 in a pilot virtual trial.
Study: NCT01333839

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: exercise training
Description: endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
Study: NCT03192527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KN015
Description: experimental drug

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Comparator.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: The drug is used for down-regulation of endogenous FSH.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Triptorelin
Description: The drug is used for down-regulation of endogenous FSH.
Study: NCT04200716

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity continuous training - session
Description: Moderate exercise continuous exercise 30 minuts session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moderate intensity continuous training - session
Description: Moderate exercise continuous exercise 30 minuts session

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training - session
Description: The high intensity interval exercise sessions are isocaloric to the moderate intensity continuous exercise, therefore, the necessary exercise time equivalent to 30 minutes of the moderate exercise continuous exercise session was calculated.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High intensity interval training - session
Description: The high intensity interval exercise sessions are isocaloric to the moderate intensity continuous exercise, therefore, the necessary exercise time equivalent to 30 minutes of the moderate exercise continuous exercise session was calculated.
Study: NCT01788306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OOPEN+BBCC
Description: Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
Study: NCT03616821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brazikumab
Description: Intravenous brazikumab on day 1, day 15, and day 43 followed by Subcutaneous brazikumab every 4 weeks beginning on day 71 through Week 50

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo on day 1, day 15, and day 43 followed by Subcutaneous placebo every 4 weeks beginning on Day 71 through Week 50.
Study: NCT02117167

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2014
Description: Target: m-TOR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: Target: FGFR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5363
Description: Target: AKT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD8931
Description: Target: HER2, EGFR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Target: MEK

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Target : VEGF, EGFR

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard maintenance for squamous NSCLC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard maintenance for squamous NSCLC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Standard maintenance for non squamous NSCLC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Standard maintenance for non squamous NSCLC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Target: PD-L1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: savolitinib
Description: target : MET

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: target : PARP
Study: NCT01114958

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin, Thiosulfate
Description: Cisplatin (150 mg/m\^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m\^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m\^2).
Study: NCT02002806

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Alcohol Injection
Description: Celiac plexus neurolysis by alcohol injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Injection
Study: NCT00216099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Folic Acid
Description: All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Description: All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
Study: NCT04053088

Intervention type: DEVICE
Intervention: INSPIRIS RESILIA Aortic Valve™
Description: Collection of patient data from patients undergoing Surgical Aortic Valve Replacement (SAVR) by usage of the INSPIRIS RESILIA aortic valve™
Study: NCT01390116

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Aged garlic extract
Description: 2 aged garlic extract capsules taken twice daily
Study: NCT03301103

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTM202
Description: PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
Study: NCT03164161

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cold pressor test
Description: Described before.
Study: NCT00605982

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI
Description: The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
Study: NCT05535491

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational and Research Hospital
Description: breathing exercise
Study: NCT03703297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Durvalumab
Description: Durvalumab IV (intravenous infusion)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tremelimumab
Description: Tremelimumab IV (intravenous infusion)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo IV (intravenous infusion)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV (intravenous infusion)
Study: NCT01720563

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Astragalus polysaccharides 500 mg
Description: PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks
Study: NCT02211898

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNS003
Study: NCT04358354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan 150 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin 85 mg/m2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-fluorouracil 400 mg/m2 iv bolus and 2400 mg/m2 civ 46 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil 400 mg/m2 iv bolus and 2400 mg/m2 civ 46 hours
Study: NCT00626418

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aplindore
Description: Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets
Study: NCT00628862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler® 4.5mg
Description: 4.5 mg inhaled twice daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol Turbuhaler® 9 mg
Description: 9 mg inhaled twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Turbuhaler® placebo
Description: placebo inhaled twice daily
Study: NCT03689699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.
Study: NCT04437888

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ketamine
Description: Ketamine versus saline placebo will be compared in order to evaluate the effects of Ketamine on patients that are pain catastrophizers
Study: NCT03689699

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: A dose of 480mg every 4 weeks as a 30 minute IV infusion for 6 doses has been selected for this study. 6 total doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Degarelix
Description: Standard treatment at a dose of 240mg subcutaneously (SQ) as a loading dose followed by 80mg SQ every 4 weeks for 4 doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986253
Description: BMS-986253 (also referred to as anti-IL8 mAb or HuMax IL8) is a fully human-sequence IgG1κ monoclonal antibody (mAb) directed against human interleukin-8 (IL-8). Subjects will be treated with an intravenous (IV) flat dose of 2400mg every 2 weeks.
Study: NCT04635358

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: Setting up hypnosis sessions

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Psychological support
Description: Setting up psychological support

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrional support
Description: Setting up nutritional support
Study: NCT04668742

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DYNAtraq
Description: Tracheostomy alignment with DYNAtraq
Study: NCT02298140

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMS reminders
Description: Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
Study: NCT01326715

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mangafodipir (Teslascan)
Description: gadolinium enhancement on contrast enhanced brain MRI.
Study: NCT01942707

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: abdominoplasty with Scarpa's Fascia
Description: During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominoplasty without Scarpa´s Facia
Description: During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
Study: NCT00708032

Intervention type: DEVICE
Group type: OTHER
Intervention: spectacles
Description: habitual spectacles

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: narafilcon A soft contact lenses
Description: narafilcon A daily disposable contact lenses
Study: NCT01131494

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor exercises for swallowing, breathing and phonation
Description: This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
Study: NCT00190216

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magnetic stimulator
Study: NCT04480827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid tablet 600mg, single dose
Description: Aramchol free acid tablet 600mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid tablet 600mg, single dose
Description: Aramchol free acid tablet 600mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid tablet 600mg, single dose
Description: Aramchol free acid tablet 600mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid tablet 600mg, single dose
Description: Aramchol free acid tablet 600mg, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid tablet 300mg, bid
Description: Aramchol acid tablet 300mg, bid for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid tablet 300mg, bid
Description: Aramchol acid tablet 300mg, bid for 12 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aramchol free acid tablet 300mg, bid
Description: Aramchol acid tablet 300mg, bid for 12 days
Study: NCT03824262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HICO-VARIOTHERM 550
Description: Warming during perioperative period.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mistral-Air Plus forced air warming device
Description: Warming during perioperative period.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mistral-Air Plus forced air warming device
Description: Warming during perioperative period.
Study: NCT02281318

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mepolizumab
Description: Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
Study: NCT02278718

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NexoBrid
Description: NexoBrid is an enzymatic debriding agent for Eschar Removal.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Surgical or Non-Surgical methods for Eschar Removal
Study: NCT03164161

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: β-endorphins evaluation in saliva
Description: Described before.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: β-endorphins evaluation in blood plasma
Description: Described before.
Study: NCT01605097

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: HDR interstitial brachytherapy
Description: 2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
Study: NCT00773188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bevacizumab [Avastin]
Description: 7.5mg/kg iv or 15mg/kg iv every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: 75mg/m2 iv according to a standard chemotherapy treatment protocol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: 15mg/m2 iv according to a standard chemotherapy treatment protocol
Study: NCT00502918

Intervention type: DEVICE
Intervention: CLM - HA Continuous Monitoring System Heart Application
Study: NCT02143882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluenz
Description: Live attenuated influenza vaccine
Study: NCT02876731

Intervention type: DEVICE
Group type: OTHER
Intervention: PET-CT
Description: NaF PET-CT

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI
Description: DWMRI
Study: NCT02281318

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% sodium chloride solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOC
Description: Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: SOC
Description: Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
Study: NCT01698255

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ENGAGE

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Psychotherapy
Study: NCT03784768

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plantar Vibration Group
Description: Patients in plantar vibration group will be received 45-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities. In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Patients in control group will be received 60-minute conventional physiotherapy session for 5-days in a week, over 4-week. Each physiotherapy sessions will consist of range of motion exercises, strengthening exercises, exercises such as activities of daily living, mobility and transfer activities.
Study: NCT01980069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sugammadex
Description: In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neostigmine
Description: In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
Study: NCT02804516

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the nurse did early mobilization
Description: the nurses know and do what is the early mobilization in ICU

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: the nurse do not do early mobilization
Description: the nurses do not know and do what is the early mobilization in ICU
Study: NCT04376502

Intervention type: RADIATION
Group type: OTHER
Intervention: Radiation Therapy
Description: Radiation therapy for all subjects will consist of treating one tumor of the treating physician's preference (40 Gray (Gy) in 5 fractions), and after a 1-week interval during which ICI is continued alone, radiation therapy will be given to a second and separate tumor (30 Gy in 5 fractions).
Study: NCT04442724

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fiducial marker placement
Description: placement of 24k gold fiducial markers surrounding the tumor site, at time of primary or re-staging bladder tumor resection

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multiparametric MRI (mpMRI)
Description: In this study, mp-MRI is defined as MRI that includes T1 \& T2 weighted sequences, diffusion weighted sequences, and Dynamic contrast enhanced (DCE) MRI sequences.